Dr Katie Chapman is an experienced biochemist and leads the Assay Biology Group at Domainex. Previously she was a Head of the Mechanism and Functional Screening Facility at the Drug Discovery Centre of Imperial College London. Prior to that she worked at GlaxoSmithKline as a Senior Scientist in the Screening and Compound Profiling Department, where she was responsible for the biochemical kinase assay portfolio, and went on to hold an in vitro Pharmacologist position in the Schizophrenia and Cognitive Disorder disease performance unit, working on late-stage projects such as the muscarinic agonist programme.
Katie has a wealth of experience working on a wide range of targets and multi-assay formats including biochemical, biophysical and cell-based assays. She has successfully worked on and delivered several Innovate UK Grant applications and can support clients by generating reports suitable for Innovate UK review.
Katie obtained her PhD from University of Leeds, working with Prof John Findlay on the structure-function relationship of melanocortin 4 receptor, a pivotal target in controlling appetite.